<DOC>
	<DOCNO>NCT02435303</DOCNO>
	<brief_summary>The purpose study determine whether Sildenafil effective treatment sustain pulmonary artery hypertension correct mitral valve disease .</brief_summary>
	<brief_title>Effect Sildenafil Sustained PAH After MV Surgery ( SUPERIOR Trial )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>New York Heart Association Functional class ( NYHA Fc ) ≥ 2 dyspnea sustain till one year previous mitral valve surgery ( repair replacement ) TR Vmax ≥ 3.5m/s echocardiography Normal leave ventricle ejection fraction ( EF ≥ 50 % ) Pulmonary vascular resistance ≥ 3 Wood Unit diastolic pressure gradient ≥ 7mmHg cardiac catheterization Other valve disease moderate degree ( ex . aortic stenosis , aortic regurgitation ) Liver cirrhosis Chronic renal failure serum creatinine ≥ 1.7mg/dL Lung disease ( ex . chronic obstructive pulmonary disease , Asthma ) Thyroid dysfunction Other cause lead pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>